Brain

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic CancerTheriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed…

11 months ago
Hyperfine, Inc. to Present at the Jefferies Global Healthcare ConferenceHyperfine, Inc. to Present at the Jefferies Global Healthcare Conference

Hyperfine, Inc. to Present at the Jefferies Global Healthcare Conference

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared…

11 months ago
Report from the Annual General Meeting 2024 of IRLAB Therapeutics ABReport from the Annual General Meeting 2024 of IRLAB Therapeutics AB

Report from the Annual General Meeting 2024 of IRLAB Therapeutics AB

GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Today, on Wednesday May 22, 2024, IRLAB Therapeutics…

11 months ago
Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide FormulationEnzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation

Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation

Updates on ETC Marketing, Inc and Ownership of ITV-1 and IPFALLEN, TX / ACCESSWIRE / May 22, 2024 / Enzolytics,…

11 months ago
Hyperfine, Inc. Celebrates ASNR 2024Hyperfine, Inc. Celebrates ASNR 2024

Hyperfine, Inc. Celebrates ASNR 2024

The 2024 ASNR Annual Meeting had a strong focus on Alzheimer’s disease care and growing excitement about ultra-low-field MRILAS VEGAS--(BUSINESS…

11 months ago
Atalanta Therapeutics Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial OfficerAtalanta Therapeutics Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer

Atalanta Therapeutics Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer

- Serena Hung, M.D., and Jeffrey Young will support company’s continued progress, including two planned IND submissions in 2025 -BOSTON--(BUSINESS…

11 months ago
Halberd/Athena GTX Research Promises a Much Brighter FutureHalberd/Athena GTX Research Promises a Much Brighter Future

Halberd/Athena GTX Research Promises a Much Brighter Future

Walt Disney once said, "All our dreams can come true if we have the courage to pursue them".JACKSON CENTER, PA…

11 months ago
IRLAB has Administered the First Dose in a Phase I Clinical Trial with the Drug Candidate IRL757IRLAB has Administered the First Dose in a Phase I Clinical Trial with the Drug Candidate IRL757

IRLAB has Administered the First Dose in a Phase I Clinical Trial with the Drug Candidate IRL757

GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 22, 2024 - IRLAB Therapeutics…

11 months ago
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research EffortsNexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

HOUSTON, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased…

11 months ago
Biodexa Announces $7 Million of Gross Proceeds from Warrant ExercisesBiodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

May 22, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds…

11 months ago